Symbolbild · KI-generiert
Recursion Pharmaceuticals, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Recursion Pharmaceuticals combines artificial intelligence and machine learning with high-throughput biological experimentation for drug discovery. Its technology platform generates large-scale biological datasets to identify disease mechanisms and find new drug candidates. The company maintains a broad pipeline across rare diseases and oncology.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Artificial Intelligence & Software sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. | RXRX | NASDAQ | 1,59 Mrd. USD |
| SkyWater Technology, Inc. | SKYT | NASDAQ | 1,60 Mrd. USD |
| Globant S.A. | GLOB | NYSE | 1,58 Mrd. USD |
| Omnicell, Inc. ($0.001 par value) | OMCL | NASDAQ | 1,61 Mrd. USD |
| Formula Systems (1985) Ltd. | FORTY | NASDAQ | 1,65 Mrd. USD |
| ChipMOS TECHNOLOGIES INC. | IMOS | NASDAQ | 1,66 Mrd. USD |
| Progress Software Corporation (DE) | PRGS | NASDAQ | 1,66 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.